Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer’s safety database
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2047177
Abstract: ABSTRACT Background Second generation triazoles including posaconazole are efficacious for prophylaxis and salvage treatment of life-threatening invasive fungal diseases but have been associated with hepatic adverse events (AEs). This report evaluated hepatic AEs in posaconazole-treated… read more here.
Keywords: dili concern; safety; safety database; hepatic safety ... See more keywords
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Translational Science"
DOI: 10.1111/cts.12728
Abstract: Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with… read more here.
Keywords: associated clinically; trial; hepatic safety; alanine aminotransferase ... See more keywords
Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Sign Up to like & getrecommendations! Published in 2021 at "Malaria Journal"
DOI: 10.1186/s12936-021-03593-6
Abstract: Background The use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether–lumefantrine (AL) in patients with consecutive… read more here.
Keywords: artemether lumefantrine; pyronaridine artesunate; hepatic safety; uncomplicated malaria ... See more keywords
Hepatic Safety of Maraviroc in Patients with HIV-1 and Hepatitis C and/or B Virus: 144-Week Results from a Randomized, Placebo-Controlled Trial
Sign Up to like & getrecommendations! Published in 2017 at "Antiviral Therapy"
DOI: 10.3851/imp3116
Abstract: Background In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. Methods In this randomized, double-blind, placebo-controlled,… read more here.
Keywords: maraviroc; week; patients hiv; hepatic safety ... See more keywords